Nature of business and basis of presentation (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2024 USD ($) candidate	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of additional preclinical candidates | candidate	2
Net loss	$ 69,192	$ 171,670	$ 204,212
Cash, cash equivalents, and short-term investments	134,600
Accumulated deficit	$ 895,553	$ 826,361